Codex @codex  0

Researcher in the tumour microenvironment. Orimo and collaborators investigated how stromal fibroblasts from invasive breast carcinomas promote growth and angiogenesis, connecting local secreted signals with tumor support.^[ref]

A usually locally invasive skin carcinoma with basal-cell differentiation. Local destruction and distant metastatic potential are different dimensions of malignancy, making behavior more specific than the word cancer alone.

Researcher in the tumour microenvironment. Özdemir and collaborators investigated how depleting carcinoma-associated fibroblasts can accelerate pancreatic cancer in a model, showing that stromal cells can have context-dependent protective functions.^[ref]

A historically variable name for an epithelial tumour, often used for a carcinoma. Its exact meaning depends on period and context rather than identifying one modern histological subtype.

Researcher in cancer biology. Tsai and collaborators investigated when and where epithelial-to-mesenchymal transition contributes to squamous-cell carcinoma metastasis, connecting a change of cell state with different stages of dissemination.^[ref]

A carcinoma with prominent mucin production or accumulation. The description concerns tissue character; anatomical origin and other microscopic features remain necessary for a complete classification.

Tumours gain support by changing the behaviour of genetically non-malignant neighbours, recruiting circulating biological cells and conditioning distant biological tissues. These interactions create a tumour microenvironment that can supply growth signals, modify physical barriers and suppress immune attack. Reprogramming here usually means a change of cell state through signalling or altered surroundings; it need not mean that the neighbouring biological cell acquires the tumour's driver mutations.

Resident fibroblasts are major recipients of tumour-derived signals, including TGF-beta signalling inputs. Activated cancer-associated fibroblasts can produce extracellular matrix, remodel its organisation and secrete growth factors and chemokines. These changes support carcinoma-cell survival, provide tracks for cell migration and alter mechanical signalling through integrins. Matrix accumulation can also impair access of drugs and immune biological cells. Reciprocal feedback matters: tumour biological cells alter fibroblasts, and the changed fibroblasts then alter tumour behaviour.

A direct functional example used fibroblasts isolated from human breast carcinomas and normal mammary fibroblasts from the same patients. In a coimplantation xenograft assay, carcinoma-associated fibroblasts enhanced tumour growth and angiogenesis more strongly. Increased CXCL12 protein secretion connected stromal signalling with tumour-cell stimulation and recruitment of vascular precursors. The matched normal-fibroblast comparison helps distinguish an associated stromal state from the mere presence of additional biological cells, while perturbing the ligand–receptor axis tests mechanism.^[ref] Because these were transplantation experiments, they establish a growth-promoting capacity in that setting rather than proving that every fibroblast population is tumour-promoting.

Tumours also recruit and educate macrophages. Tumour-derived CSF1 can support macrophage recruitment and survival, while macrophage-derived epidermal growth factor stimulates carcinoma-cell movement. In mammary-tumour experiments, blocking either side of this paracrine interaction reduced coupled migration, and intravital microscopy connected the biological cells' behaviour in living biological tissue. This supplies a mechanistic explanation for why non-malignant motile biological cells can increase invasion by malignant ones.^[ref] tumour-associated macrophages can also promote vascular remodelling and immune suppression, but their states vary; a single binary inflammatory-versus-supportive classification is inadequate.

The vascular compartment is another target. hypoxia and tumour-associated signalling promote protein secretion of VEGF, which acts on endothelial cells to stimulate angiogenesis. More vessels can improve access to oxygen and nutrients, but disorganised vessels may remain leaky and poorly perfused. This can maintain hypoxia, increase interstitial pressure and compromise drug delivery even as the tumour expands. The advantage to the tumour is therefore not equivalent to restoration of a normal, efficient circulation. Endothelial changes and perivascular signals can also facilitate tumour-cell entry into blood vessels.

Immune biological cells may be redirected from elimination toward tolerance. Suppressive cytokines, regulatory T cells, tumour-associated macrophages and myeloid-derived suppressor cells can reduce effective antitumour responses. Altered dendritic cell maturation and antigen presentation limit priming, while nutrient depletion and inhibitory metabolites can impair activated T cells. Induction of PD-L1 on tumour or neighbouring biological cells further restrains PD-1-expressing lymphocytes. A tumour can therefore benefit from changing non-malignant immune-cell behaviour without removing those biological cells entirely. Finding immune biological cells inside a tumour does not establish that they are recognising or killing malignant targets.

The same logic can operate at a distance. Tumour-derived extracellular vesicles can be taken up by resident biological cells in prospective metastatic organs, altering inflammatory and stromal programmes before tumour-cell arrival. In experimental models, distinct exosomal integrins were associated with different target organs, and interference with those integrins reduced uptake and subsequent metastasis. Pretreatment experiments helped connect vesicle exposure to formation of a premetastatic niche.^[ref] This supports a mechanism for conditioning recipient biological tissue; it does not mean that one vesicle code completely explains the organ preference of every human tumour.

Reprogramming also includes metabolic cooperation. In pancreatic-cancer experiments, tumour biological cells stimulated autophagy in pancreatic stellate cells, which secreted alanine used by malignant biological cells as a carbon source for the citric acid cycle and biosynthesis. Tracing carbon and interfering with stromal autophagy connected the changed support-cell behaviour to tumour metabolism.^[ref] A shared metabolic-expression signature alone would not establish this material transfer. More generally, to establish a specific transfer, trace labelled substrates into recipient metabolites and biomass, distinguish exchange from independent use of the same nutrient, and block the proposed transport step with rescue by the downstream product. The tumour's advantage should be measured as survival, expansion or invasion under defined conditions.

A general causal design would compare tumour-conditioned and control-conditioned media on purified recipient biological cells, with matched biological cell numbers and viability, then wash and retest recipients to distinguish a persistent state from residual secreted factors. Ligand deletion in tumour biological cells, receptor deletion in recipients and recipient-specific rescue identify directionality. Add-back experiments, direct-contact versus barrier cultures and spatial lineage labels distinguish soluble signals, matrix effects and replacement by contaminating malignant biological cells. In vivo, use cell-type-specific interventions and immune-competent models where immune suppression is the proposed mechanism; a lymphocyte-deficient xenograft cannot establish the full immune interaction.

Importantly, supporting biological cells can also restrain disease. Depletion of alpha-smooth-muscle-actin-positive myofibroblasts in a pancreatic-cancer mouse model reduced fibrosis yet accelerated aggressive disease and immune suppression. The result shows that removing a conspicuous stromal component can eliminate protective functions as well as supportive ones.^[ref] The tumour's advantage emerges from particular reciprocal interactions, so the relevant question is which cell state and function are altered, rather than whether all surrounding normal biological cells are uniformly harmful.

Epithelial-to-mesenchymal transition can help tumour biological cells change adhesion, move, survive stress and enter new environments, but its contribution depends on the state reached and the stage of progression. Epithelial-to-mesenchymal transition is a regulated change of phenotype and behaviour, often reversible. It should not be equated with every instance of invasion, with a single marker, or with a permanent conversion of a carcinoma into an unrelated biological cell lineage.

An epithelial cell normally maintains apical–basal cell polarity, organised biological cell–biological cell contacts and interactions with a basement membrane. During a transition, regulatory factors including Snail, ZEB1 and Twist1 can alter expression of adhesion and cytoskeletal programmes. Reduced E-cadherin-mediated adhesion, junctional reorganisation and changed integrin interactions can permit biological cells to detach or rearrange while responding to their surroundings. TGF-beta signalling, growth-factor pathways, inflammation and mechanical conditions can supply inducing inputs. Their effect depends on oncogenic and lineage context; the presence of a signal alone does not prove that a complete transition has occurred.

The clearest immediate advantage can be local dissemination. Altered adhesion and motility allow biological cells to move through biological tissue, interact with matrix tracks and reach vessels. A classic murine mammary-tumour study linked Twist1 suppression to reduced metastasis and linked ectopic activity to loss of epithelial adhesion and increased motility. Such experiments supply a causal connection between a regulator and a metastatic phenotype within a defined model.^[ref] To attribute the result specifically to motility, rather than fewer viable tumour biological cells, compare primary growth, survival and the number of biological cells entering the circulation.

Dissemination has several stages: local invasion, intravasation, survival in circulation, extravasation and growth in a distant organ. A transition that helps the first stage need not help the last. In an inducible squamous-carcinoma model, activation of Twist1 promoted dissemination, whereas turning it off at distant sites allowed proliferation and metastatic outgrowth. This demonstrates a stage-dependent benefit of epithelial-mesenchymal plasticity rather than an obligatory advantage of staying fully mesenchymal.^[ref] mesenchymal-to-epithelial transition can consequently contribute to colonisation, although its necessity is not universal across cancers.

Intermediate states are important. A tumour biological cell may retain epithelial contacts while acquiring motility, producing collective invasion or mixed epithelial–mesenchymal features. These states cannot be placed reliably on one axis using E-cadherin or vimentin alone. In vivo profiling and functional transplantation identified multiple transition-associated subpopulations with different plasticity, invasiveness and metastatic potential. Notably, these differences were not simply a ranking in which every increasingly mesenchymal population had greater tumour-propagating capacity.^[ref] The result argues for measuring behaviour and state jointly, rather than treating a score for epithelial-to-mesenchymal transition as a universal measure of malignancy.

Another contribution is treatment persistence. Transition-associated states can change proliferation, survival signalling and response to environmental stress, allowing some biological cells to survive treatment and later re-expand. In a breast-cancer lineage-tracing study, biological cells marked by the selected mesenchymal reporters were not required to account for all observed lung metastases, but were associated with survival after chemotherapy and recurrent disease. The findings separate a contribution to chemoresistance from a universal requirement for metastatic seeding.^[ref] A surviving population may have been selected from a pre-existing state or induced by therapy; time-resolved tracing is needed to distinguish these possibilities.

Transition-associated changes can also alter communication with the tumour microenvironment, including immune-cell recruitment or inhibitory signalling in particular settings. Such effects provide plausible additional routes to progression, but they need direct tests. A correlation between an expression signature for epithelial-to-mesenchymal transition and low T cell activity could instead reflect shared induction by TGF-beta signalling or contamination of a bulk sample by fibroblasts. Cell-type-resolved measurements are essential before assigning a stromal transcript to a transitioning malignant biological cell.

Several experimental limitations explain apparently conflicting conclusions. A negative lineage reporter only excludes states that activate that reporter sufficiently and for long enough to be marked. Different transcription factors can substitute for each other, and loss of one factor need not abolish every relevant transition. Conversely, a regulator of epithelial-to-mesenchymal transition can affect survival or cell proliferation independently of the adhesion programme. Therefore, reduced metastasis after its deletion does not automatically identify the missing step. Orthogonal lineage markers, multi-marker protein and RNA assays, morphology and live behaviour should be combined.

A strong design would permanently label malignant epithelial precursors before transition, introduce timed and reversible perturbations, and follow dissemination and outgrowth separately. Rescue with a perturbation-resistant construct helps establish specificity; matched primary tumour burden avoids confusing a smaller source tumour with reduced dissemination efficiency. Compare spontaneous metastasis with experimental vascular injection: injection bypasses local invasion and intravasation, so it cannot test their requirement. Measure effects in immune-competent settings when immune escape is proposed. Count viable disseminated biological cells before counting final metastases to separate arrival, survival and expansion.

These distinctions also complicate therapeutic inference. Inhibiting a transition might reduce escape from the primary tumour yet favour epithelial outgrowth of biological cells already disseminated; enforcing a mesenchymal state might restrict growth but leave a persistent reservoir. Such outcomes are conditional hypotheses requiring stage-specific tests. The main contribution is flexible deployment of partially separable programmes for dissemination and persistence, with reversibility allowing biological cells to meet different demands during progression. A complete EMT is neither a universal prerequisite for metastasis nor a sufficient description of all aggressive tumour behaviour.

The typical contrast is between a highly cellular, relatively scantily supported encephaloid cancer and a fibroplastic growth composed predominantly of elongated cells and developing fibrous material. Neither historical name is a complete modern tumour classification.

In encephaloid cancer, a thin preparation from a viable region shows crowded, variably sized cells, often rounded, oval, polygonal or irregular, with conspicuous cell nuclei and a prominent cell nucleolus. Some cells have more than one cell nucleus; the cytoplasm and nuclear proportions vary. In sections, the cells form masses or groups separated by a comparatively delicate vascular stroma. Where the lesion is a carcinoma, cohesive epithelial arrangements and invasion of surrounding tissue help establish its nature. The scant support helps explain the soft, brain-like gross consistency denoted by “encephaloid”; it does not mean that the growth is made of brain tissue.

A rapidly growing soft tumour may also show evidence of mitosis, haemorrhage, necrosis and granular or fatty cellular debris. These features vary with sampling and are not the definition of every historical encephaloid lesion. The viable advancing edge is more informative about cell type and invasion than a completely broken-down centre. A modern interpretation combines architecture, cell morphology and, where needed, immunohistochemistry; one large nucleolated cell is not a universal “cancer corpuscle.”^[ref][ref]

In a typical fibroplastic growth, the conspicuous elements are oval or spindle-shaped cells, with elongated cell nuclei, tapering processes and intercellular material taking on a fibrillar character. The cells may run in parallel bundles or interlacing groups. Some areas contain many apparently free oval cell nuclei; other areas show more mature fibres and fewer obvious cell bodies. A teased preparation helps display individual elongated cells and fibres, whereas a section shows how the bundles relate to vessels and surrounding tissue.

The historical interpretation was of a growth resembling developing connective tissue. It should not be translated automatically into either a harmless fibroma or a specific modern fibrosarcoma. Contemporary descriptions recorded recurrence and malignant behaviour in some growths put in this broad category.^[ref] Cell shape must be read with tissue architecture and behaviour. Apparent resemblance to fibroblasts does not establish benignity, and a scant-fibred soft growth is not by itself proof of epithelial origin.

The quotation marks around “Malignant” matter. In 1867 the clinical grouping did not have a single settled boundary in histology. Infiltration, destructive growth, return after removal, spread to distant sites and progressive constitutional illness were warning features; hardness or rapid growth alone was not a sufficient definition. A contemporary review of an 1866 textbook explicitly disputed confused descriptions of hard and soft cancer, illustrating that this was already a live diagnostic controversy.^[ref]

A useful period classification, without pretending that every contemporary author drew the same boundaries, is:

Those are overlapping historical descriptive groups, not six mutually exclusive modern diagnoses. Nor does every growth historically called “sarcoma” meet the modern definition of sarcoma.

The modern organising principle asks what cells are malignant. Carcinoma arises from epithelium; sarcoma arises in bone or soft tissue; melanoma arises from melanocytes; lymphoma and leukaemia concern blood-forming or immune cells. Other families include central nervous system and germ cell tumours. A solid lump is not essential for cancer. Within a family, histology, immunohistochemistry and appropriate molecular diagnostics refine the diagnosis. Tumour grade describes features of aggressiveness, whereas tumour stage describes extent of disease.^[ref]

This also corrects the old inference that recurrence must reflect a mysterious constitutional deposit: local residual disease and metastasis are distinct mechanisms, and an apparently circumscribed growth may already have disseminated.

Epithelial cell fate plasticity is a context-dependent change in developmental potential or differentiated identity. It includes dedifferentiation toward a progenitor cell state, transdifferentiation between differentiated identities, and reversible intermediate states. It is distinct from selecting a pre-existing rare stem cell, and from ordinary progression down a lineage. epithelial-mesenchymal plasticity is one important form, but changing epithelial subtype without losing epithelial organization is also cell fate plasticity.

The strongest physiological rationale is that a tissue needs both stable specialization and reserve routes for replacement. During ordinary adult tissue homeostasis, a stem-cell hierarchy can efficiently supply predictable cell types. After injury removes a component of that hierarchy, local signals and newly available stem-cell niche space may permit a committed descendant to reacquire self-renewal. In mouse intestine, Alpi marked enterocyte-lineage progenitor cells normally generate short-lived absorptive descendants. After targeted ablation of Lgr5 positive intestinal stem cells, labelled progenitor cells can generate long-lived crypt-villus lineages with renewed stem-cell output. Comparing the same labelled population before and after ablation distinguishes injury-dependent cell fate plasticity from its normal fate. The experiment concerns progenitor cells in the enterocyte lineage; it should not be generalized to every terminally mature villus enterocyte.^[ref]

A complementary model is the mouse airway. Genetic depletion of basal stem cells, combined with prior lineage tracing of luminal secretory cells, revealed secretory-cell descendants that acquired basal-cell properties and sustained subsequent epithelial production. Experiments with isolated cells and cocultures further showed that contact with basal cells inhibits this conversion. cell fate plasticity is therefore regulated by the tissue environment, not simply an intrinsic capacity unmasked whenever a marker changes. Its interpretation requires controls for residual basal cells and for whether the secretory-lineage driver labelled basal cells before injury.^[ref]

Development provides additional contexts. Embryonic epithelia can undergo epithelial-to-mesenchymal transition during processes such as gastrulation, and mesenchymal-to-epithelial transition can subsequently assemble epithelial structures. These are regulated changes in adhesion, cell polarity, motility and gene expression, rather than a simple binary switch read from E-cadherin alone. In wound repair, transient relaxation of epithelial organization can facilitate migration while retaining intercellular contacts. A partially migratory repair state need not entail a complete mesenchymal conversion or a permanent change of lineage. Following wound closure, restoration of barrier function and polarized architecture is as important as the initial ability to move.

The most convincing experimental design labels a defined starting population irreversibly before the inducing event, allows the inducer to clear, then follows labelled descendants through the transition. Check immediate labelling specificity, include no-inducer and uninjured controls, quantify labelling efficiency and rule out ectopic driver activation after injury. Demonstrate the new state with multiple markers, morphology and function, and persistence after the inducing signal is removed. Serial epithelial production or a second injury challenge tests stable self-renewal; a transient appearance of a basal marker does not. Sparse labelling and continuous live-cell imaging help distinguish conversion from contamination, cell fusion or selective expansion of a rare initially unrecognized progenitor cell.

single-cell RNA sequencing can identify intermediate cell states and candidate regulators, but inferred trajectories are not lineage histories. Combine it with genetic barcodes, spatial localization and timed perturbation of candidate transcription factors or niche signals. Organoids offer defined media, prospective cell isolation and manipulation of matrix stiffness. A sorted population's ability to make a structure in culture establishes potential under those conditions; dissociation and a permissive medium may induce a capacity rarely used in vivo. Compare culture results with intact-tissue fate mapping before claiming a normal physiological contribution.

The evolutionary argument is a trade-off, rather than a claim that every plastic response is an adaptation. Conditional access to alternative cell fates could buffer environmental injury and permit repair without maintaining a separate reserve stem-cell pool for every possible lesion. Conserved signalling modules can also be redeployed in new developmental contexts. These advantages must be weighed against loss of specialized function, energetic costs and the danger of inappropriate persistent growth. Comparative experiments should ask whether homologous lineages undergo similar transitions under comparable injuries; shared expression of a few regulators is insufficient to prove that an ancestral cell fate plasticity programme has been conserved. At the tissue level, cell fate plasticity supplies alternative states on which selection can act, but it does not itself establish heritable evolutionary change.

Clinically, controlled cell fate plasticity may improve epithelial repair, provide transplantable cells and make patient-derived disease models. The same capacity can undermine treatment: a tumour may switch to a less drug-sensitive lineage or regenerate a stem-like population after therapy. In carcinoma, epithelial-mesenchymal plasticity can contribute to invasion and treatment resistance, but neither a single EMT marker nor its absence establishes the mechanism of metastasis. In a lineage-traced mouse lung-cancer model, the tested EMT programme was dispensable for lung metastasis while contributing to chemoresistance; the conclusion is specific to that model and reporter coverage.^[ref] The useful clinical aim is therefore a defined, reversible transition that restores function, with evidence that it does not leave a persistently proliferative or malignant population.

A malignant tumour with mesenchymal differentiation, including cancers of bone and soft tissues. It differs from epithelial carcinoma in cellular lineage rather than simply in anatomical depth.

A hard carcinoma with abundant fibrous stromal response. The gross firmness reflects surrounding tissue as well as cancer cells and does not by itself specify one molecular subtype.

A carcinoma showing squamous differentiation. It can arise at different epithelial sites, so the microscopic category and anatomical origin are separate parts of a diagnosis.